GIPR and diabetes mellitus: Interestingly, 4-hydroxybenzoic acid 2-bromobenzylidene hydrazide (4H2BH) is a small-molecular-weight compound that has been reported to inhibit both GIPR and glucagon receptor activity (Franklin et al. 2011), with obvious dual benefits for obesity-related diabetes.